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 Abstract
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Background- Tamoxifen is used to treat breast cancer and cancer recurrences. After administration, tamoxifen is converted into
two more potent antitumor compounds, 4OH-tamoxifen and endoxifen by the CYP3A4/5 and 2D6 enzymes in human. These active
compounds are inactivated by the same UDP-glucuronosyltransferases isoforms as those involved in the metabolism of morphine.
Importantly, cancer-associated pain can be treated with morphine, and the common metabolic pathway of morphine and tamoxifen
suggests potential clinically relevant interactions.
Methods- Mouse liver microsomes were used to determine the impact of morphine on 4OH-tamoxifen metabolism in vitro. For in
vivo experiments, female mice were first injected with tamoxifen alone and then with tamoxifen and morphine. Blood was
collected, and LC-MS/MS was used to quantify tamoxifen, 4OH-tamoxifen, N-desmethyltamoxifen, endoxifen, 4OH-tamoxifen-
glucuronide and endoxifen-glucuronide.
Results- In vitro, we found increased Km values for the production of 4OH-tamoxifen-glucuronide in the presence of morphine,
suggesting an inhibitory effect on 4OH-tamoxifen glucuronidation. Conversely, in vivo morphine treatment decreased
4OH-tamoxifen levels in the blood while dramatically increasing the formation of inactive metabolites 4OH-tamoxifen-glucuronide
and endoxifen-glucuronide.
Conclusions- Our findings emphasize the need for caution when extrapolating results from in vitro metabolic assays to in vivo drug
metabolism interactions. Importantly, morphine strongly impacts tamoxifen metabolism in mice. It suggests that tamoxifen
efficiency could be reduced when both drugs are co-administered in a clinical setting, e.g. to relieve pain in breast cancer patients.
Further studies are needed to assess the potential for tamoxifen-morphine metabolic interactions in humans.
  
 Contribution to the field
Our study has been designed to determine if morphine modulates tamoxifen metabolism in vitro and in vivo. Breast cancer is the
most common and deadliest women cancer. Among anti-breast cancer drugs, tamoxifen decreases breast cancer recurrence and
mortality rates. Tamoxifen is a pro-drug metabolized in the liver by enzymes leading to two more potent anti-tumour compounds,
endoxifen and 4OH-tamoxifen (30-100 fold). Then, UDP-glucuronosyltransferase enzymes catalyze their inactivation into
glucuronides. Cancer-associated pain (e.g. metastases, surgeries) represents a major problem solved by the use of analgesic drugs,
including morphine. Morphine and tamoxifen share some catabolic pathway leading to morphine-glucuronide metabolites.
Therefore drug-drug interactions could be expected and interfere with the expected therapeutical effect. As no data are available
on tamoxifen-morphine potential interaction, we have focused our attention on such drug-drug interactions in vitro using mass
spectrometry. To get rid of inter-individual variations, our in vivo protocol was designed to use each animal as his own control of
tamoxifen metabolism. If a difference occurs, it may lead to rethink co-analgesic procedures in the case of breast cancer
treatment.
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ABSTRACT 18 
Background- Tamoxifen is used to treat breast cancer and cancer recurrences. After 19 
administration, tamoxifen is converted into two more potent antitumor compounds, 4OH-20 
tamoxifen and endoxifen by the CYP3A4/5 and 2D6 enzymes in human. These active 21 
compounds are inactivated by the same UDP-glucuronosyltransferases isoforms as those 22 
involved in the metabolism of morphine. Importantly, cancer-associated pain can be treated 23 
with morphine, and the common metabolic pathway of morphine and tamoxifen suggests 24 
potential clinically relevant interactions.  25 
Methods- Mouse liver microsomes were used to determine the impact of morphine on 26 
4OH-tamoxifen metabolism in vitro. For in vivo experiments, female mice were first injected 27 
with tamoxifen alone and then with tamoxifen and morphine. Blood was collected, and LC-28 
MS/MS was used to quantify tamoxifen, 4OH-tamoxifen, N-desmethyltamoxifen, 29 
endoxifen, 4OH-tamoxifen-glucuronide and endoxifen-glucuronide. 30 
Results- In vitro, we found increased Km values for the production of 4OH-tamoxifen-31 
glucuronide in the presence of morphine, suggesting an inhibitory effect on 4OH-tamoxifen 32 
glucuronidation. Conversely, in vivo morphine treatment decreased 4OH-tamoxifen levels 33 
in the blood while dramatically increasing the formation of inactive metabolites 4OH-34 
tamoxifen-glucuronide and endoxifen-glucuronide. 35 
Conclusions- Our findings emphasize the need for caution when extrapolating results from 36 
in vitro metabolic assays to in vivo drug metabolism interactions. Importantly, morphine 37 
strongly impacts tamoxifen metabolism in mice. It suggests that tamoxifen efficiency could 38 
be reduced when both drugs are co-administered in a clinical setting, e.g. to relieve pain in 39 
breast cancer patients. Further studies are needed to assess the potential for tamoxifen-40 
morphine metabolic interactions in humans. 41 
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 48 
BACKGROUND 49 
Breast cancer is the most common and deadliest cancer diagnosed in women, even though 50 
major advances in screening and treatment have been made the last twenty years [1]. In 51 
estrogen receptor (ER)-positive breast tumors, the main strategy of breast anticancer drugs 52 
is to either antagonize ER signaling and/or decrease estrogen synthesis to prevent cancer cell 53 
proliferation. Among those drugs, tamoxifen is a selective estrogen receptor modulator 54 
(SERM) used for decades to decrease breast cancer recurrence [2]. Nowadays,  , tamoxifen 55 
remains one of the major treatment for breast cancer, especially in countries with limited 56 
health care resources [3]. 57 
Tamoxifen is a pro-drug metabolized mostly in the liver by the phase I cytochrome P450 58 
(CYP) 2D6 and 3A4/5 enzymes [4]. In human, hydroxylation of tamoxifen (CYP2D6) leads 59 
to 4OH-tamoxifen that can be further processed into endoxifen (via CYP3A4/5) through N-60 
desmethylation. These two major metabolites are 30-100 fold more potent than tamoxifen 61 
itself and are responsible for its anti-tumoral activity. 62 
 In addition, N-desmethylation of tamoxifen generates the N-desmethyltamoxifen 63 
intermediate (CYP3A4/5) that is further metabolized into endoxifen through CYP2D6-64 
mediated hydroxylation.  65 
Endoxifen is the major metabolite of tamoxifen in humans. Alternatively, in mice, even 66 
though CYP2D6 isoform is absent, 4OH-tamoxifen is the main anticancer product of 67 
tamoxifen suggesting that other CYP2D isoforms, such as CYP2D22, could be involved in 68 
its metabolism [4; 5].  69 
Phase II metabolizing enzymes including Uridine 5'-diphospho (UDP)-70 
glucuronosyltransferases (UGT1A10, 1A4, 1A8, 2B7 and 2B15) convert active tamoxifen 71 
metabolites into inactive 4OH-tamoxifen-glucuronide and endoxifen-glucuronide (Fig. 1) 72 
[6]. Approximately 75% of a given dose of tamoxifen is excreted into the biliary tract as 73 
inactive glucuronides [7].  74 
Cancer-associated pain resulting from metastases, anticancer treatment or surgery 75 
represents a major problem which is treated with analgesic drugs including morphine, 76 
codeine and/or paracetamol [8]. Morphine remains the gold standard for mild and severe 77 
pain relief despite side effects that limit its chronic use [9]. In humans, morphine acts on Mu 78 
opioid receptors (MORs) to produce analgesia. Its metabolism in the liver and brain leads 79 
mainly to the formation of morphine-3-glucuronide (M3G) [10] and morphine-6-80 
glucuronide (M6G) [10; 11; 12]. In human, morphine-glucuronidation is catalyzed by 81 
UGT2B7 and to a lower extent by a number of other UGT isoforms (UGT1A10, UGT1A1, 82 
1A3, 1A6, 1A8, 1A9, 2A1 and UGT2B21) [9; 13; 14]. However, in mice, UGT2B7, the 83 
major enzyme involved in morphine metabolism in human, is absent but its activity is 84 
rescued by UGT2B21 and UGT2B36 [14; 15; 16]. 85 
 Drug-drug interactions, resulting in either enzyme inhibition or induction, are a major 86 
limitation for the use of co-treatments [17]. Usually, these drug-drug interactions are initially 87 
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studied in vitro and then in vivo [18]. While in vitro studies provide interesting results, their 88 
interpretation has proven to be complex when translated to in vivo drug metabolism [18]. 89 
Although anti-cancer agents share common catabolic pathways with many opiates, the 90 
impact of their co-administration on the metabolism and thus on the activity of anticancer 91 
drugs remains unexplored. These potential interactions between analgesic and anticancer 92 
drug metabolism could be used to treat more efficiently breast cancer. Therefore, as a proof 93 
of concept, we have investigated in mice whether morphine can alter tamoxifen metabolism. 94 
 95 
METHODS 96 
Animals 97 
Experiments were performed with 11 to 29 weeks-old female C57BL/6J mice (23±4g; 98 
Charles River, L’Arbresle, France). Animals were housed according to a 12h light-dark 99 
cycle, at a temperature of 22°C±2°C and provided with food and water ad libitum. All 100 
procedures were performed in accordance with European directives (2010/63/EU) and were 101 
approved by the regional ethics committee and the French Ministry of Agriculture (license 102 
No. APAFIS#16827-2018092113192911 v4 to Y.G.). 103 
 104 
 105 
Blood collection 106 
The tail of the mouse was anaesthetized locally with a cutaneous application of 107 
lidocaine/prilocaïne 5% (Zentiva, Paris, France). After 5min, a small incision was performed 108 
at the end of the tail and 10µl of blood was collected using a calibrated capillary (Minicaps 109 
End-to-End10µl; Hischmann, Eberstadt Germany).  110 
 111 
 112 
Tamoxifen and morphine injections 113 
Female mice were injected intraperitoneally (i.p., calibrated Hamilton syringe) with 114 
10mg/kg of tamoxifen (in 90% olive oil/10% ethanol, v/v; Sigma Aldrich, Lyon, France), 115 
and then with NaCl 0.9% at 0h, 1h and 2h following tamoxifen administration (Fig. 2). Blood 116 
was collected by tail vein sampling (see above) just before and at 1h, 2h, 4h, 8h, 24h and 117 
48h after tamoxifen injection (Fig. 2).  A second injection of tamoxifen was then performed 118 
at 48h and immediately followed by an injection of either 10mg/kg of morphine-HCl (diluted 119 
in 0.9% NaCl; Francopia, Paris, France) or saline solution (0.9% NaCl only). Mice then 120 
received two additional injections of morphine or saline at 1h and 2h after the second 121 
tamoxifen dose. Blood was collected at 1h, 2h, 4h, 8h, 24h and 48h after the second 122 
tamoxifen injection (Fig. 2).  123 
 124 
 125 
Sample preparation  126 
The blood was transferred from the capillary into a microtube containing 10µl of heparin 127 
and frozen at -20°C for later analysis. On the next day, blood was thawed and 10µl of an 128 
internal standard (IS; see below) and 100µl of ice-cold acetonitrile (ACN; Thermo Scientific, 129 
San Jose, USA) were added. The samples were next vortexed and centrifuged at 20 000g 130 
during 15min at 4°C. The supernatants were collected, dried under vacuum and suspended 131 
in 15µL of 50% methanol/0,1% formic acid (v/v; Sigma Aldrich) prior to LC-MS/MS 132 
analysis. 133 
 134 
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 135 
Microsome preparation 136 
Liver tissues were collected from 10 week old male C57/BL6J mice. Samples were pooled 137 
and homogenized with an Ultra Turrax instrument (Ika, Staufen, Germany) in 10ml of 138 
extraction buffer (100mM Na3PO4 buffer pH 7.4, 0.32 M Sucrose, 1mM EDTA, 0.1mM 139 
DTT, protease inhibitor, cOmplete Mini, EDTA-free, Roche, Basel, Switzerland). The 140 
homogenate was then sonicated (2x10s, 100 W) and centrifuged for 12min at 2000g (4°C). 141 
The supernatant was transferred into polycarbonate ultracentrifuge tubes (Beckman 142 
Instruments, Palo Alto, USA), completed with extraction buffer and centrifuged 40min at 143 
10 000g and 4°C in a type-70 Ti Rotor (Beckman Coulter, Brea, USA). The resulting 144 
supernatant was then centrifuged for 130min at 130 000g (4°C), and the pellet obtained was 145 
suspended in 800µl of storage buffer (0.1M Na3PO4 buffer pH 7.4, 0.5mM EDTA, 0.1mM 146 
DTT, 20% glycerol; Sigma Aldrich) and frozen. Protein concentration was determined using 147 
the Bradford method (Protein Assay, Bio-Rad, Marnes-la-Coquette, France).  148 
 149 
Enzymatic Activity Assay 150 
100µg of liver microsomes were used to perform 4OH-tamoxifen glucuronidation assays. 151 
First, increasing concentrations of 4OH-tamoxifen (10, 20, 40, 50, 60, 70, 80, 100, 125, 150, 152 
200, 250 and 300µM; LGC Standard, Molsheim, France) with a fixed concentration of 153 
morphine (500µM) were dried under vacuum. Morphine was suspended in 4mM MgCl2 154 
adjusted with H2O, and each 4OH-tamoxifen concentration was diluted with 69µl of the 155 
morphine-containing mix.  156 
Microsomes were incubated for 15min at 4°C in the presence of alamethicin (30µg/mg of 157 
protein; Santa Cruz Biotechnology, Heidelberg, Germany) and Tris-HCl buffer (400mM) 158 
adjusted with H2O. Then, 75µL of microsome were added to each 4OH-tamoxifen 159 
concentration and tubes were equilibrated at 37°C during 5min. The enzymatic reactions 160 
were started with the addition of 6µl of UDPGA to a final concentration of 5mM. Reactions 161 
were stopped 20s later with 900µl of cold 100% methanol. Samples were then diluted (1:5), 162 
and an IS (see below) was added to each sample. Samples were centrifuged for 15min at 163 
20 000g, and 4°C and the supernatants dried under vacuum, then suspended in 45µl of 4% 164 
methanol/0.1% formic acid (v/v) prior to LC-MS/MS analysis. Km and Vmax were obtained 165 
with a Michaelis-Menten plot following a nonlinear curve fit with the least-squares method 166 
(Graphpad Prism 6 software). 167 
 168 
LC-MS/MS instrumentation and analytical conditions 169 
Analyses were performed with a Dionex Ultimate 3000 HPLC system (Thermo Scientific) 170 
coupled with a triple quadrupole Endura mass spectrometer. Xcalibur v2.0 software was 171 
used to control the system (Thermo Electron, Villebon Sur Yvette, France). Samples were 172 
loaded onto an Accucore RP-MS column (150 x 1 mm, 2μm, flow of 90µl/min; Thermo 173 
Electron) heated at 40°C. Buffer A was 1% ACN/ 98.9% H2O/ 0.1% formic acid (v/v/v), 174 
whereas buffer B was 99.9% ACN / 0.1% formic acid (v/v). The gradient used is detailed in 175 
Supplementary Table 1.  176 
Electrospray ionization was achieved in the positive mode with the spray voltage set at 177 
3500 V. Nitrogen was used as the nebulizer gas, and the ionization source was heated to 178 
250°C. Desolvation (nitrogen) sheath gas was set to 18 Arb and Aux gas was set to 7 Arb. 179 
Ion transfer tube was heated at 297°C. Q1 and Q2 resolutions were set at 0.7 FWHM, 180 
whereas collision gas (CID, argon) was set to 2 mTorr. Identification of the compounds was 181 
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based on precursor ion, selective fragment ions and retention times. Selection of the 182 
monitored transitions and optimization of collision energy and RF Lens parameters were 183 
manually determined (see Supplementary Table 1 for details). Qualification and 184 
quantification were performed in MRM mode using Quan Browser software (Thermo 185 
Scientific).  186 
 187 
 188 
Statistics 189 
Statistical analysis was performed using GraphPad Prism 6 Software. Results were 190 
presented as mean values ± standard error of the mean (SEM). Groups were compared using 191 
multiple t tests. 192 
  193 
 194 
RESULTS 195 
Enzymatic study in vitro 196 
As 4OH-tamoxifen is the major active metabolite of tamoxifen in mice, in vitro 197 
experiments were performed on mouse liver microsomes to study the impact of 500µM of 198 
morphine on the glucuronidation of 4OH-tamoxifen. Morphine was used at 500µM to 199 
determine the Km of the glucuronidation of 4OH-tamoxifen as this concentration 200 
corresponds to the Km previously determined for morphine glucuronidation in mice [12; 201 
19]. As shown in Figure 3, morphine significantly affects the production of 4OH-tamoxifen-202 
glucuronide. Specifically, morphine significantly reduced the production of 4OH-tamoxifen-203 
glucuronide when 10 to 50 µM and 70µM of tamoxifen were used. Km values for the 204 
production of 4OH-tamoxifen-glucuronide in the absence and presence of morphine, as 205 
determined by the Michaelis-Menten equation, were 68µM and 98,6µM (+45%), 206 
respectively. 207 
These results indicate that morphine reduces 4OH-tamoxifen glucuronidation in vitro. 208 
 209 
Study of tamoxifen metabolism in vivo  210 
First, we determined whether multiple injections of tamoxifen would alter its own 211 
metabolism (Fig. 2 and Fig. 4A). Blood was collected before and 1h, 2h, 4h, 8h, 24h and 212 
48h after the first (Fig. 4A, white part) and the second injection of tamoxifen (Fig. 4A, grey 213 
part). Tamoxifen, 4OH-tamoxifen and endoxifen-glucuronide concentrations in the blood 214 
did not vary significantly at any time point between the two tamoxifen injections (Fig. 4B). 215 
In contrast, a significant increase in the concentrations of 4OH-tamoxifen-glucuronide, N-216 
desmethyltamoxifen and endoxifen was observed. Accordingly, drug metabolic ratios (i.e. 217 
the concentration ratio of a metabolite compared to its parent molecule) were significantly 218 
altered at different time points (Fig. 5A-F). The ratio of endoxifen/N-desmethyltamoxifen 219 
was significantly elevated at 4h and 8h compared to the first injection suggesting an increase 220 
in endoxifen synthesis (Fig. 5C). In a more dramatic manner, 4OH-tamoxifen 221 
glucuronidation was increased by 1.5-2 fold at all time points compared to the first injection 222 
(Fig. 5F). Similarly, the t=2h ratio of endoxifen-glucuronide to its parent molecule endoxifen 223 
showed a 3-fold increase compared to the first injection (Fig. 5E). On the other hand, no 224 
difference was observed for 4OH-tamoxifen/tamoxifen (Fig. 5A), N-225 
desmethyltamoxifen/tamoxifen (Fig. 5B), and endoxifen/4OH-tamoxifen ratios (Fig. 5D). 226 
Together, these results indicate that tamoxifen metabolism is slightly potentiated following 227 
two subsequent injections of the drug. 228 
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As morphine has a short half-life in mice (30min), we have performed three injections of 229 
morphine to reach adequate concentrations in the blood (Supplementary Fig. 1). The 230 
highest concentrations of morphine and M3G in the blood were reached after 2h (1599±336 231 
pmol/ml and 9773±1274 pmole/ml, respectively). Morphine was still present after 8h, 232 
allowing a long-lasting competition with tamoxifen metabolism. 233 
Then, female mice were injected twice with tamoxifen (at 0h and 48h) in addition to 234 
morphine (at 48h, 49h and 50h) and blood samples were collected (Fig. 6A). Following 235 
morphine injections, the blood concentrations of tamoxifen, 4OH-tamoxifen, 4OH-236 
tamoxifen-glucuronide, endoxifen and endoxifen-glucuronide were significantly increased 237 
compared to the first injection of tamoxifen (Fig. 6B). Only a tendency was observed for N-238 
desmethytamoxifen. More importantly, ratios between 4OH-tamoxifen/tamoxifen (Fig. 7A) 239 
were significantly decreased by 1/2-1/5 fold 1h, 2h and 8h after the injection of morphine, 240 
suggesting that 4OH-tamoxifen was processed into its metabolites at a faster rate in the 241 
presence of morphine. Indeed, the ratios of 4OH-tamoxifen-glucuronide/4OH-tamoxifen 242 
showed a significant increase (2-3 fold) at every time point (Fig. 7F). Similarly, endoxifen-243 
glucuronide/endoxifen ratios (Fig. 7E) were dramatically increased (1.5-4 fold) at 2h, 4h 244 
and 8h after the injection of morphine. On the other hand, the ratios of endoxifen/N-245 
desmethyltamoxifen (Fig. 7C) and endoxifen/4OH-tamoxifen (Fig. 7D) were not altered by 246 
morphine administration. Together, these results indicate that the inactivation of tamoxifen 247 
and its active metabolites is exacerbated in the presence of equimolar amounts of morphine. 248 
 249 
 250 
DISCUSSION 251 
Repeated tamoxifen treatment potentiates glucuronide formation in vivo 252 
Our results show that the blood formation pattern of N-desmethyltamoxifen and endoxifen 253 
is slightly modified in vivo after two subsequent tamoxifen treatments. Indeed, we observed 254 
a higher peak concentration in the case of N-desmethyltamoxifen and a slower elimination 255 
for endoxifen upon the second administration of tamoxifen. Furthermore, analysis of 256 
metabolic ratios revealed an increase in 4OH-tamoxifen-glucuronide and endoxifen-257 
glucuronide formation compared to their parent drugs when animals received a second 258 
injection of tamoxifen. Such an increase of glucuronidation can be related to induction of 259 
the expression of UGTs present in the liver occurring 48h after the first injection of 260 
tamoxifen. Indeed, it has been described that several xenobiotics are able to promote UGT 261 
expression by acting on regulatory elements in the cell [20]. Tamoxifen acts as a selective 262 
modulator on the ER which in turn modulates the activity of numerous transcription factors 263 
implicated in the regulation of gene expression. Importantly, tamoxifen has been shown to 264 
increase the expression of CYP enzymes involved in its own metabolism, such as CYP3A4 265 
[21]. In the same manner, one may hypothesize that the first injection of tamoxifen induced 266 
the expression of UGTs, resulting in a potentiation of 4OH-tamoxifen and endoxifen 267 
glucuronidation upon the second treatment. 268 
 Surprisingly, despite an increase in tamoxifen glucuronidation, we observed no concurrent 269 
decrease in the concentrations of 4OH-tamoxifen or endoxifen. The main degradation 270 
pathway of tamoxifen is glucuronidation, but significant amounts of its two active 271 
metabolites are eliminated through sulfation. Several sulfotransferase (SULT) isoforms 272 
(1A1, 1E1, 2A1) have been implicated in the degradation of 4OH-tamoxifen [22]. In 273 
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addition, it has been shown in vitro that tamoxifen metabolites are able to inhibit SULT2A1 274 
through mixed or non-competitive inhibition [23]. Therefore, it is possible that our first 275 
tamoxifen administration inhibited SULT expression towards 4OH-tamoxifen and 276 
endoxifen. Thus, the balance between glucuronidation and sulfation could be modified 277 
without affecting 4OH-tamoxifen or endoxifen levels. Nevertheless, this hypothesis remains 278 
to be tested.  279 
 280 
 281 
Morphine increases glucuronidation of tamoxifen active metabolites 282 
Morphine was expected to reduce the glucuronidation of tamoxifen active metabolites 283 
through direct competition on the UGT-binding site as observed in vitro. Surprisingly, our 284 
results showed a dramatic increase in the levels of all active and inactive metabolites of 285 
tamoxifen when morphine was co-administered. The significant elevated levels of tamoxifen 286 
found in the blood after the coinjection with morphine may explain the increase observed 287 
for all compounds. This increase is likely to rely on differences of absorption due to drug-288 
drug interactions with morphine rather than variability in tamoxifen injections. This point is 289 
strengthen by the fact that 19 mice were injected using a calibrated Hamilton syringe. Ratio 290 
between metabolites and their corresponding parent molecules were established to normalize 291 
the metabolite production with the tamoxifen injections. Analysis of the ratio revealed that 292 
morphine dramatically decreased the amount of 4OH-tamoxifen relative to that of its 293 
prodrug in the blood of tamoxifen-treated mice. This decrease is likely related to the 294 
concurrent massive increase of the glucuronidation of 4OH-tamoxifen and endoxifen.   295 
It seems improbable that morphine would act as a cofactor of UGTs allowing faster 296 
glucuronidation since it did not occur in our in vitro experiments. A potential impact of 297 
morphine on the entry of tamoxifen in hepatocytes is also unlikely because tamoxifen is 298 
known to cross the cell membrane passively [7], whereas morphine influx relies on 299 
transporters including organic cation transporter 1 (OCT1) [24]. The last type of common 300 
molecular targets in the metabolism of tamoxifen and morphine are MRP and MDR 301 
transporters driving M3G, 4OH-tamoxifen, endoxifen, 4OH-tamoxifen-glucuronide and 302 
endoxifen-glucuronide out of the cell [7; 16; 25; 26]. One hypothesis involving those 303 
transporters may be that morphine decreases the efflux rate of tamoxifen active metabolites 304 
(and thus their glucuronidation rate). Additional studies are needed to decipher the molecular 305 
mechanism underlying this atypical change in tamoxifen metabolism. 306 
In conclusion, co-administration of morphine in mice appears to promote the inactivation 307 
of the potent 4OH-tamoxifen and endoxifen metabolites. In light of these findings, we 308 
hypothesize that morphine could reduce the potency of tamoxifen anticancer treatment in 309 
mice. Further studies should determine if the impact of morphine on tamoxifen metabolism 310 
is sufficient to result in changes in anticancer activity at therapeutic doses.  311 
 312 
Strengths and limitations 313 
We chose to associate morphine with tamoxifen to develop our methodology as it was 314 
expected to be a simple model focusing primarily on the glucuronidation process. Morphine 315 
is mainly metabolized by UGTs and was not expected to impact CYP activity. Morphine and 316 
tamoxifen co-treatments are given after surgeries or in the case of severe cancer pain [27]. 317 
Otherwise, codeine and/or paracetamol are widely prescribed [8]. In human, these two 318 
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compounds are metabolized by the same CYPs (6D6/3A4) and UGTs (1A10, 1A4, 1A8, 2B7 319 
and 2B15) [28; 29] as tamoxifen and might have a more complex impact on tamoxifen 320 
metabolic pathways [30; 31].  321 
A main limitation of our study is that tamoxifen and morphine metabolisms differ in mice 322 
compared to humans. 4OH-tamoxifen is the major active mouse metabolite whereas 323 
endoxifen is found at greater concentrations in human serum. However, our approach using 324 
the isotopic dilution allowed us to observed non-negligible levels of both endoxifen and 325 
endoxifen-glucuronide in the blood of tamoxifen-treated mice. In mice, the Cyp2d gene 326 
cluster display nine functional genes (Cyp2d9, Cyp2d10, Cyp2d11, Cyp2d12, Cyp2d13, 327 
Cyp2d22, Cyp2d26, Cyp2d34 and Cyp2d40), whereas humans only have one (CYP2D6) [4]. 328 
Therefore, the presence of endoxifen suggest that CYP2D6 activity is rescued by an 329 
alternative CYP.  330 
In addition, morphine is only metabolized into M3G in mice versus M3G and M6G in 331 
humans [32; 33]. Nevertheless, both species eliminate tamoxifen and morphine 332 
predominantly through glucuronidation. UGT2B7 [15], the main UGT involved in morphine 333 
metabolism in humans, is absent in mice. However, morphine and tamoxifen 334 
glucuronidation could be compensated by other enzymes including the mouse homologs of 335 
human UGT2B6, 2C9, 2C19, 3A4/5 [34], UGT2B36 and UGT2B21 [14; 15]. These 336 
differences lead to a tamoxifen half-life of 27h in humans and 6.8h in mice [4], as well as a 337 
morphine half-life of 30 min in mice and 2h in humans [32; 33]. Despite the existence of 338 
mouse equivalents to human CYP and UGT isoforms, major differences in isoform sequence 339 
and expression patterns limit the extrapolation of mouse data to humans. The development 340 
of humanized mouse models for CYP and UGT genes will allow to overcome such issues 341 
[34; 35].  342 
Drug-drug interactions can lead to severe adverse effects and predicting these interactions 343 
in vivo is challenging. Thus, the Food and Drug Administration (FDA) and European 344 
Medicines Agency (EMA) are frequently publishing new guidelines regarding in vitro and 345 
in vivo drug-drug interaction studies [36]. We have used an in vivo methodology to monitor 346 
modulations of tamoxifen metabolism. Intraperitoneal injections of tamoxifen were used 347 
instead of oral administration (the typical route of administration in humans) in order to 348 
better control the given amounts of tamoxifen and morphine [37]. Indeed, the most used 349 
method is intraperitoneal injection, because the amount of administered compound can be 350 
better controlled, but delivery by oral gavage is also possible.  However, oral administration 351 
suffers from significant first-pass metabolism [38], which limits absorption [39] and 352 
introduces inter-individual variability in drug metabolism [40]. The pharmacokinetics of 353 
tamoxifen were obtained by quantification of tamoxifen and its metabolites following an 354 
initial injection (10mg/kg). Then, a second injection was used to determine its 355 
pharmacokinetics in the absence or the presence of the competing drug morphine. Therefore, 356 
it was possible to accurately compare tamoxifen pharmacokinetics in the same animal to 357 
assess its potential interaction with morphine in vivo. It is however important to determine 358 
whether an injection of the drug of interest can induce adaptive processes responsible for 359 
differences in its metabolism following a second injection or chronic treatment. 360 
 361 
Conclusions 362 
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In this study, we have investigated the effects of morphine on tamoxifen metabolism in 363 
vitro and in vivo. We have shown that in vitro morphine inhibits 4OH-Tamoxifen 364 
glucuronidation. Conversely, morphine reduced the blood levels of 4OH-tamoxifen in mice, 365 
while the inactivation of tamoxifen active compounds through glucuronidation greatly 366 
increased. 367 
Our results suggest that morphine co-treatment could dramatically affect tamoxifen 368 
efficacy, and emphasize the need to test more common analgesics (e.g. codeine or 369 
paracetamol) in humans to re-evaluate the impact of pain treatments on anti-cancer drug 370 
metabolism and pharmacological activity.   371 
 372 
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ABBREVIATIONS 402 
ACN, acetonitrile; ADME, absorption, distribution, metabolism, and/or excretion; AF, 403 
formic acid; AI, aromatase-inhibitors; CYP, cytochrome P450; ER, estrogen receptor; 404 
i.p., injected intraperitoneally; IS, internal standard; LC-MS/MS, liquid chromatography-405 
mass spectrometry/mass spectrometry; M3G, morphine-3-glucuronide; M6G, morphine-406 
6-glucuronide; MOR, Mu opioid receptors; SEM, standard error of the mean; SERM, 407 
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selective estrogen receptor modulator; TDM, therapeutic drug monitoring; UGT, UDP-408 
glucuronosyltransferases; SULT, sulfotransferase. 409 
 410 
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FIGURES 550 
Fig. 1- Simplified metabolic pathway of tamoxifen in humans. Compounds in green and 551 
red are the active and inactive metabolites of tamoxifen, respectively. 552 
 553 
Fig. 2- Protocol used to study tamoxifen-morphine drug-drug interactions. 554 
 555 
Fig. 3-. Morphine (500µM) inhibits the formation of 4OH-tamoxifen-glucuronide in 556 
vitro. A t test using the Holm-Sidak method was performed to compare each concentration 557 
of 4OH-tamoxifen. n=7 for tamoxifen alone and n=5 in the presence of morphine; *, p<0.05. 558 
Values are means ± SEM. 559 
 560 
Fig. 4- Tamoxifen metabolism is affected by a prior injection. Effect of 2 subsequent 561 
injections of tamoxifen (10 mg/kg i.p.) on the levels of tamoxifen and its metabolites. A, 562 
Protocol. Injections of NaCl 0.9% at 0h, 1h and 2h are not represented. B, Left panels, levels 563 
of tamoxifen, 4OH-tamoxifen, N-desmethyltamoxifen, endoxifen, 4OH-tamoxifen-564 
glucuronide and endoxifen-glucuronide during 96h. Right panels correspond to the 565 
superimposition of the first 0-48h (white area) and last 48-96h (grey area). The grey area 566 
corresponds to an increase in the quantity of the corresponding molecule after the second 567 
injection (48-96h). Multiple t tests with the Holm-Sidak correction were applied. Values are 568 
means ± SEM. *, p<0.05. 569 
 570 
Fig. 5- Tamoxifen potentiates its own metabolism. Ratio between metabolites and parent 571 
compounds. (A) 4OH-tamoxifen/tamoxifen, (B) N-desmethyltamoxifen/tamoxifen, (C) 572 
endoxifen/N-desmethyltamoxifen, (D) endoxifen/4OH-tamoxifen, (E) endoxifen-573 
glucuronide/endoxifen and (F) 4OH-tamoxifen-glucuronide/4OH-tamoxifen. N are 574 
indicated within columns.  Values are means ± SEM. T tests; *, p<0.05; **,p<0.001. 575 
 576 
Fig. 6- Morphine increases tamoxifen metabolism. Effect of 3 injections of morphine 577 
(10 mg/kg i.p.) on the blood concentrations of tamoxifen, 4OH-tamoxifen, N-578 
desmethyltamoxifen, endoxifen4OH-tamoxifen-glucuronide and endoxifen-glucuronide. A, 579 
Protocol. Injections of NaCl 0.9% at 0h, 1h and 2h are not represented. B, Left panels, levels 580 
of tamoxifen, 4OH-tamoxifen, N-desmethyltamoxifen, endoxifen, 4OH-tamoxifen-581 
glucuronide and endoxifen-glucuronide during 96h. Right panels correspond to the 582 
superimposition of the first 0-48h (white area) and last 48-96h (grey area). Grey area 583 
corresponds to an increase of the quantity of the corresponding molecule after the second 584 
injection (48-96h).  Values are means ± SEM. *, p<0.05 ; **, p<0.01; ***, p<0.001 585 
 586 
Fig. 7- Morphine promotes the inactivation of tamoxifen through increased 587 
glucuronidation. Effect of 3 injections of morphine (10 mg/kg i.p.) on the ratio between 588 
metabolites and parent compounds. (A) 4OH-tamoxifen/tamoxifen, (B) N-589 
desmethyltamoxifen/tamoxifen, (C) endoxifen/N-desmethyltamoxifen, (D) endoxifen/4OH-590 
tamoxifen, (E) endoxifen-glucuronide/endoxifen and (F) 4OH-tamoxifen-591 
glucuronide/4OH-tamoxifen. N are indicated within columns. T tests; *, p<0.05 ; ***, 592 
p<0.001; ****, p<0.0001. 593 
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